Nimenrix

RSS

meningococcal group A, C, W 135 and Y conjugate vaccine

Authorised
This medicine is authorised for use in the European Union.

Overview

Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning).

The vaccine contains substances from the outer coat of the bacterium N. meningitidis.

This EPAR was last updated on 14/11/2019

Authorisation details

Product details
Name
Nimenrix
Agency product number
EMEA/H/C/002226
Active substance
  • Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid / Neisseria meningitidis serogroup W-135 polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid
International non-proprietary name (INN) or common name
meningococcal group A, C, W 135 and Y conjugate vaccine
Therapeutic area (MeSH)
Meningitis, Meningococcal
Anatomical therapeutic chemical (ATC) code
J07AH08
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Revision
28
Date of issue of marketing authorisation valid throughout the European Union
20/04/2012
Contact address

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

28/02/2019 Nimenrix - EMEA/H/C/002226 - II/0084

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
4 ratings